Finding a low-cost way to detect endemic Burkitt Lymphoma earlier
Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Looking at molecular makeup and MRIs to characterise infant ependymoma.
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.